Zobrazeno 1 - 10
of 210
pro vyhledávání: '"Noritoshi, Nagaya"'
Autor:
Shunsuke Ohnishi, Noritoshi Nagaya
Publikováno v:
International Journal of COPD, Vol 2008, Iss Issue 4, Pp 509-514 (2008)
Shunsuke Ohnishi, Noritoshi NagayaDepartment of Regenerative Medicine and Tissue Engineering, National Cardiovascular Center Research Institute, Suita, Osaka, JapanAbstract: COPD is a major cause of chronic morbidity and mortality worldwide, and ther
Externí odkaz:
https://doaj.org/article/be0fd3efd4b64f87bafd53f5155afd71
Autor:
Keisuke Miki, Ryoji Maekura, Noritoshi Nagaya, Masamitsu Nakazato, Hiroshi Kimura, Shinsuke Murakami, Shunsuke Ohnishi, Toru Hiraga, Mari Miki, Seigo Kitada, Kenji Yoshimura, Yoshitaka Tateishi, Yasuji Arimura, Nobuhiro Matsumoto, Masanori Yoshikawa, Kenichi Yamahara, Kenji Kangawa
Publikováno v:
PLoS ONE, Vol 7, Iss 5, p e35708 (2012)
BACKGROUND: Pulmonary cachexia is common in advanced chronic obstructive pulmonary disease (COPD), culminating in exercise intolerance and a poor prognosis. Ghrelin is a novel growth hormone (GH)-releasing peptide with GH-independent effects. The eff
Externí odkaz:
https://doaj.org/article/c76703c4192f42899e3d921b88933619
Autor:
Miki Yokokawa, Shunsuke Ohnishi M.D., Ph.D., Hatsue Ishibashi-Ueda, Hiroaki Obata, Kentaro Otani, Yoshinori Miyahara, Koichi Tanaka, Wataru Shimizu, Kazuo Nakazawa, Kenji Kangawa, Shiro Kamakura, Soichiro Kitamura, Noritoshi Nagaya
Publikováno v:
Cell Transplantation, Vol 17 (2008)
Mesenchymal stem cells (MSCs) are multipotent cells that differentiate into a variety of lineages including myocytes and vascular endothelial cells. However, little information is available regarding the therapeutic potential of MSCs in patients with
Externí odkaz:
https://doaj.org/article/e87bfbd956fc47feb70ae96a5fef0161
Autor:
Soichiro Kitamura, Hisao Ogawa, Toshihisa Anzai, Hajime Ohgushi, Noritoshi Nagaya, Teruo Noguchi, Wataru Shimizu, Kazuhiro Satomi, Takeshi Yagyu, Takeshi Nakatani, Satoshi Yasuda, Kenji Kangawa, Kaori Doi, Kengo Kusano
Publikováno v:
Circulation journal : official journal of the Japanese Circulation Society. 83(7)
Background Mesenchymal stem cells (MSCs), which have the potential to differentiate into cardiomyocytes or vascular endothelial cells, have been used clinically as therapy for cardiomyopathy. In this study, we aimed to evaluate the long-term follow-u
Publikováno v:
Journal of Tissue Engineering and Regenerative Medicine. 12:e395-e397
Many clinical studies of regenerative medicine using bone marrow-derived mesenchymal stem cells (MSCs) have been conducted globally. We initiated clinical studies using MSCs in 2001, and have now treated over 100 cases with patients aged 0–92 years
Autor:
Noritoshi Nagaya, Hidezo Mori, Tatsuya Shimizu, Yoshiki Sawa, Osamu Ishida, Toshikatsu Yagihara, Ikuo Hagino, Teruo Okano
Publikováno v:
Translational Research. 165:631-639
Adipose-derived stem cells (ASCs) are a promising resource for cell transplantation therapy for damaged heart tissue. Cell death in the graft early after transplantation represents the main cause of unsatisfactory therapeutic efficacy, but tissue-eng
Autor:
Kunio Matsumoto, Yoshiki Sakai, Hiroaki Obata, Masanori Yoshikawa, Katsuya Sakai, Atsuhiro Nakamura, Noritoshi Nagaya, Hiroshi Kimura, Kaoru Hamada
Publikováno v:
Circulation Journal. 77:2127-2133
Background Continuous administration of prostacyclin has improved the survival of patients with pulmonary arterial hypertension (PAH). However, this treatment has some problems, including its short duration of activity and difficult delivery. Therefo
Autor:
Teruo Noguchi, Hisao Ogawa, Satoshi Yasuda, Shunichi Miyazaki, Hiroshi Hosoda, Manabu Matsumoto, Noritoshi Nagaya, Yu Kataoka, Isao Morii, Kenji Kangawa
Publikováno v:
The Tohoku Journal of Experimental Medicine. 231:235-242
Ghrelin is a novel growth hormone-releasing peptide isolated from the stomach and possesses various cardioprotective effects, including energy balance improvement and regulation of autonomic nervous system activity. We investigated the changes in ser
Publikováno v:
Journal of tissue engineering and regenerative medicine. 12(1)
Many clinical studies of regenerative medicine using bone marrow-derived mesenchymal stem cells (MSCs) have been conducted globally. We initiated clinical studies using MSCs in 2001 and have now treated over 100 cases with patients aged 0-92 years. I
Autor:
Chiaki Nakanishi, Shu Takabatake, Shunsuke Ohnishi, Masa-aki Kawashiri, Kenshi Hayashi, Kenichi Yamahara, Toshinari Tsubokawa, Tetsuo Konno, Masakazu Yamagishi, Noritoshi Nagaya
Publikováno v:
Circulation Journal. 75(9):2260-2268
金沢大学医薬保健研究域医学系
Background: Mesenchymal stem cells (MSC) are multipotent and reside in bone marrow (BM), adipose tissue and many other tissues. However, the molecular foundations underlying the differences in prolifera
Background: Mesenchymal stem cells (MSC) are multipotent and reside in bone marrow (BM), adipose tissue and many other tissues. However, the molecular foundations underlying the differences in prolifera